Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities

References

• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• LewingtonSWhitlockGClarkeRProspective Studies CollaborationBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deathsLancet200737096021829183918061058
   PubMed Web of Science ®Google Scholar
• GradyDHerringtonDBittnerVCardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement study follow-up (HERS II)JAMA20022881495712090862
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRLRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trialJAMA2002288332133312117397
   PubMed Web of Science ®Google Scholar
• LawMRMorrisJKWaldNJUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ2009338b166519454737
   PubMed Web of Science ®Google Scholar
• StrandbergTESalomaaVVNaukkarinenVAVanhanenHTSarnaSJMiettinenTALong-term mortality after 5-year multifactorial primary prevention of cardiovascular disease in middle-aged menJAMA19912669122512291870247
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics ProgramThe Lipid Research Clinics Coronary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA198425133513646361299
   PubMed Web of Science ®Google Scholar
• Coronary Drug ProjectClofibrate and niacin in coronary heart diseaseJAMA197523143603811088963
   PubMed Web of Science ®Google Scholar
• RavnskovUCholesterol lowering trials in coronary heart disease: frequency of citation and outcomeBMJ1992305684415191638188
   PubMed Web of Science ®Google Scholar
• MuldoonMFManuckSBMatthewsKALowering cholesterol concentration and mortality: a quantitative rewiew of primary prevention trialsBMJ199030167473093142144195
   PubMed Web of Science ®Google Scholar
• OliverMFPrevention of coronary heart disease – propaganda, promises, problems, and prospectsCirculation1986731193510083
   PubMed Web of Science ®Google Scholar
• BrugtsJJYetginTHoeksSEThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ2009338b237619567909
   PubMed Web of Science ®Google Scholar
• PaciaroniMBogousslavskyJStatins and stroke preventionExpert Rev Cardiovasc Ther20097101231124319814666
   PubMedGoogle Scholar
• RibeiroRAZiegelmannPKDuncanBBImpact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patientsInt J Cardiol12202011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• TaylorFWardKMooreTHStatins for the primary prevention of cardiovascular diseaseCochrane Database Syst Rev20111CD00481621249663
   PubMed Web of Science ®Google Scholar
• ShafiqNMalhotraSPandhiPGroverAThe “Statinth” wonder of the world: a panacea for all illnesses or a bubble about to burstJ Negat Results Biomed20054315788096
   PubMedGoogle Scholar
• RahimiKMajoniWMerhiAEmbersonJEffect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trialsEur Heart J232012 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMILLUMINATE InvestigatorsEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med2007357212109212217984165
   PubMed Web of Science ®Google Scholar
• KasteleinJJPAkdimFStroesESGENHANCE InvestigatorsSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med2008358181431144318376000
   PubMed Web of Science ®Google Scholar
• TaylorAJVillinesTCStanekEJExtended-release niacin or ezetimibe and carotid intima-media thicknessN Engl J Med2009361222113212219915217
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• DavignonJBeneficial cardiovascular pleiotropic effects of statinsCirculation200410923 Suppl 13943
   Web of Science ®Google Scholar
• CorreaVJrGusMFuchsFDDoes the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?Expert Rev Cardiovasc Ther20108677577920528635
   PubMedGoogle Scholar
• MesserliFHPintoLTangSSImpact of systemic hypertension on the cardiovascular benefits of statin therapy – a meta-analysisAm J Cardiol2008101331932518237593
   PubMed Web of Science ®Google Scholar
• ThompsonAMHuTEshelbrennerCLReynoldsKHeJBazzanoLAAntihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysisJAMA2011305991392221364140
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• BaysHEMaccubbinDMeehanAGKuznetsovaOMitchelYBPaoliniJFBlood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patientsClin Ther200931111512219243712
   PubMed Web of Science ®Google Scholar